share_log

Oppenheimer Reiterates Outperform on Relay Therapeutics, Lowers Price Target to $25

Benzinga ·  May 6 07:58

Oppenheimer analyst Matthew Biegler reiterates Relay Therapeutics (NASDAQ:RLAY) with a Outperform and lowers the price target from $33 to $25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment